Israel - English - Ministry of Health

fresenius medical care israel p.b., ltd. - calcium chloride dihydrate; glucose monohydrate; magnesium chloride hexahydrate; sodium (s) - lactate; sodium chloride - solution for peritoneal dialysis - sodium (s) - lactate 3.925 g / 1 l; glucose monohydrate 25 g / 1 l; magnesium chloride hexahydrate 0.1017 g / 1 l; calcium chloride dihydrate 0.1838 g / 1 l; sodium chloride 5.640 g / 1 l - sodium chloride - end-stage (decompensated) chronic renal failure of any origin which can be treated with peritoneal dialysis.

Israel - English - Ministry of Health

fresenius medical care israel p.b., ltd. - calcium chloride dihydrate; glucose monohydrate; magnesium chloride hexahydrate; sodium (s) - lactate; sodium chloride - solution for peritoneal dialysis - sodium (s) - lactate 3.925 g / 1 l; glucose monohydrate 16.50 g / 1 l; magnesium chloride hexahydrate 0.1017 g / 1 l; calcium chloride dihydrate 0.2573 g / 1 l; sodium chloride 5.640 g / 1 l - sodium chloride - end-stage (decompensated) chronic renal failure of any origin which can be treated with peritoneal dialysis.

Israel - English - Ministry of Health

fresenius medical care israel p.b., ltd. - calcium chloride dihydrate; glucose monohydrate; magnesium chloride hexahydrate; sodium (s) - lactate; sodium chloride - solution for peritoneal dialysis - sodium (s) - lactate 3.925 g / 1 l; glucose monohydrate 25 g / 1 l; magnesium chloride hexahydrate 0.1017 g / 1 l; calcium chloride dihydrate 0.2573 g / 1 l; sodium chloride 5.640 g / 1 l - sodium chloride - end-stage (decompensated) chronic renal failure of any origin which can be treated with peritoneal dialysis.

Israel - English - Ministry of Health

fresenius medical care israel p.b., ltd. - calcium chloride dihydrate; glucose monohydrate; magnesium chloride hexahydrate; sodium (s) - lactate; sodium chloride - solution for peritoneal dialysis - sodium (s) - lactate 3.925 g / 1 l; glucose monohydrate 46.75 g / 1 l; magnesium chloride hexahydrate 0.1017 g / 1 l; calcium chloride dihydrate 0.1838 g / 1 l; sodium chloride 5.640 g / 1 l - sodium chloride - end-stage (decompensated) chronic renal failure of any origin which can be treated with peritoneal dialysis.

Israel - English - Ministry of Health

fresenius medical care israel p.b., ltd. - calcium chloride dihydrate; glucose monohydrate; magnesium chloride hexahydrate; sodium (s) - lactate; sodium chloride - solution for peritoneal dialysis - sodium (s) - lactate 3.925 g / 1 l; glucose monohydrate 46.75 g / 1 l; magnesium chloride hexahydrate 0.1017 g / 1 l; calcium chloride dihydrate 0.2573 g / 1 l; sodium chloride 5.640 g / 1 l - sodium chloride - end-stage (decompensated) chronic renal failure of any origin which can be treated with peritoneal dialysis.

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

شركة مستودع الأدوية الأردني - the jordan drugstore co - deferasirox 90 milligram/1 tablet - 90 milligram/1 tablet

Israel - English - Ministry of Health

sanofi israel ltd - valproic acid; valproic acid as sodium - tablets prolonged release - valproic acid 145 mg; valproic acid as sodium 333 mg - valproic acid - epilepsy:treatment of generalized or partial epilepsy secondary epilepsy and mixed forms of epilepsy. bipolar disorders: treatment of manic episode in bipolar disorder when lithium is contraindicated or not tolerated. the continuation of treatment after manic episode could be considered in patients who have responded to valproic acid for acute mania.

Israel - English - Ministry of Health

novartis israel ltd - adalimumab - solution for injection - adalimumab 50 mg/ml - adalimumab - rheumatoid arthritis hyrimoz in combination with methotrexate is indicated for:  the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. hyrimoz can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.adalimumab has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function, when given in combination with methotrexate. juvenile idiopathic arthritispolyarticular juvenile idiopathic arthritis:hyrimoz in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (dmards). hyrimoz can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate . adalimumab has not been studied in patients aged less than 2 years. enthesitis-related arthritis:hyrimoz is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapyaxial spondyloarthritisankylosing spondylitis (as): hyrimoz is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. axial spondyloarthritis without radiographic evidence of as: hyrimoz is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of as, but with objective signs of inflammation by radiological and/or laboratory tests including mri and serum crp levels , who have had an inadequate response to, or are intolerant to, non - steroidal anti-inflammatory drugs. psoriatic arthritis hyrimoz is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate. adalimumab has been shown to reduce the rate of progression of peripheral joint damage as measured by x-ray in patients with polyarticular symmetrical subtypes of the disease and to improve physical function. psoriasis hyrimoz is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy. paediatric plaque psoriasis hyrimoz is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies.hidradenitis suppurativa (hs)hyrimoz is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic hs therapy. crohn’s disease hyrimoz is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active crohn’s disease who have had an inadequate response to conventional therapy. hyrimoz is indicated for reducing signs and symptoms and inducing clinical remission in these patients if they have also lost response to or are intolerant to infliximab.paediatric crohn's disease hyrimoz is indicated for the treatment of moderately to severely active crohn's disease in paediatric patients (from 6- years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and corticosteroid, and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies ulcerative colitis hyrimoz is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6- mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies.paediatric ulcerative colitis hyrimoz is indicated for the treatment of moderately to severely active ulcerative colitis in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including corticosteroids and/or 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies.uveitis hyrimoz is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroidsparing, or in whom corticosteroid treatment is inappropriate.paediatric uveitis hyrimoz is indicated for the treatment of chronic non-infectious uveitis in paediatric patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.intestinal behcet’s diseasehyrimoz is indicated for the treatment of intestinal behcet’s disease in patients who have had an inadequate response to conventional therapy.

Israel - English - Ministry of Health

eisai israel ltd., israel - lenvatinib as mesilate - hard capsule - lenvatinib as mesilate 10 mg - lenvatinib - lenvima is indicated for the treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/hürthle cell) thyroid carcinoma (dtc), refractory to radioactive iodine (rai).lenvima is indicated in combination with everolimus for the treatment of adult patients with advanced clear cell renal cell carcinoma (rcc) following one prior vascular endothelial growth factor (vegf)-targeted therapy.lenvima is indicated as monotherapy for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (hcc) who have received no prior systemic therapy.lenvima, in combination with pembrolizumab, is indicated for the treatment of adult patients with advanced or recurrent endometrial carcinoma who have disease progression on or following prior treatment with a platinum containing therapy and who are not candidates for curative surgery or radiation.lenvima is indicated in combination with pembrolizumab for the first-line treatment of adult patients with advanced rcc.

Israel - English - Ministry of Health

eisai israel ltd., israel - lenvatinib as mesilate - hard capsule - lenvatinib as mesilate 4 mg - lenvatinib - lenvima is indicated for the treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/hürthle cell) thyroid carcinoma (dtc), refractory to radioactive iodine (rai).lenvima is indicated in combination with everolimus for the treatment of adult patients with advanced clear cell renal cell carcinoma (rcc) following one prior vascular endothelial growth factor (vegf)-targeted therapy.lenvima is indicated as monotherapy for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (hcc) who have received no prior systemic therapy.lenvima, in combination with pembrolizumab, is indicated for the treatment of adult patients with advanced or recurrent endometrial carcinoma who have disease progression on or following prior treatment with a platinum containing therapy and who are not candidates for curative surgery or radiation.lenvima is indicated in combination with pembrolizumab for the first-line treatment of adult patients with advanced rcc.